Posted by Michael Wonder on 23 Mar 2022
StemCyte has submitted its application for a biologics license for its allogeneic umbilical cord haematopoietic progenitor cell product "HPC-Cord Blood", to the US FDA
22 March 2022 - The BLA has been accepted for quality review and StemCyte anticipates licensure in 2023
The biologics license application for the "HPC-Cord Blood" product, was submitted to FDA on 7 January 2022, and StemCyte was officially notified on 8 March 2022, that the submission was acceptable to enter the biologics license quality review process.
